EGFR and non-small cell lung carcinoma: It is approved as a first-line treatment for patients with EGFRm advanced NSCLC and for patients with EGFR T790M advanced NSCLC following progression on an EGFR-TKI, and has efficacy in patients with NSCLC central nervous system (CNS) metastases9–11.